NCCN Guidelines® Insights - Non-Hodgkin’s Lymphomas, Version 3.2016
Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin’s lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient’s eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL.
This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Non-Hodgkin’s Lymphomas
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Non-Hodgkin’s Lymphomas
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.
INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Steven M. Horwitz, MD, Panel Member, has disclosed that he receives grant/research support from Amgen Inc., Celgene Corporation, Infinity Pharmaceuticals, Kyowa Hakko Kirin Co., Ltd., Millennium Pharmaceuticals, Inc., Seattle Genetics, and Spectrum Pharmaceuticals; he receives consulting fees/honoraria from Celgene Corporation, HUYA Bioscience International, Infinity Pharmaceuticals, Janssen Pharmaceutica Products, LP, Seattle Genetics, and Spectrum Pharmaceuticals; and is a scientific advisor for Kyowa Hakko Kirin Co., Ltd. and Millennium Pharmaceuticals, Inc.
Andrew D. Zelenetz, MD, PhD, Panel Chair, has disclosed that he receives consulting fees/honoraria from Amgen Inc.; Axess Oncology; Celgene Corporation; Gilead Sciences, Inc.; GlaxoSmithKline; Hospira, Inc.; Janssen Pharmaceutica Products, LP; Medscape, LLC; Roche Laboratories, Inc.; Takeda Pharmaceuticals North America, Inc.; and The France Foundation. He receives grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline; Janssen Pharmaceutica Products, LP, and Roche Laboratories, Inc.
Leo I. Gordon, MD, Panel Vice-Chair, has disclosed that he is a scientific advisor for Aura Sense Therapeutics.
William G. Wierda, MD, PhD, Panel Vice-Chair, has disclosed that he receives consulting fees/honoraria from AbbVie; Ascerta; Celgene Corporation; Emergent BioSolutions Inc.; Genentech, Inc; Genzyme Corporation; Gilead Sciences; GlaxoSmithKline; Karyopharm Therapeutics Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics, Inc.; Roche Laboratories, Inc.; and sanofi-aventis U.S. He receives grant/research support from and is a scientific advisor for AbbVie, Ascerta, Emergent BioSolutions Inc.; Genentech, Inc.; Gilead Sciences; GlaxoSmithKline; Karyopharm Therapeutics Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics, Inc.; Roche Laboratories, Inc. He is a scientific advisor for Celgene Corporation, Genzyme Corporation, Merck & Co., Inc., and sanofi-aventis U.S.; and receives grant/research support from Juno Therapeutics and Kite Pharma, Inc.
Pierluigi Porcu, MD, Panel Member, has disclosed that he is a scientific advisor for Kyowa Hakko Kirin Co., Ltd. and Actelion Pharmaceuticals Ltd. He has received honoraria/consulting fees from Celgene Corporation; and research support from Infinity Pharmaceuticals, Innate Pharma S.A., Kyowa Hakko Kirin Co., Ltd, miRagen Therapeutics, Seattle Genetics, and Shape Pharmaceuticals, Inc.
Mary Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships.
Hema Sundar, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-16-009-H01-P
All clinicians completing this activity will be issued a certificate of participation.
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation